ClinicalTrials.gg
TerminatedNCT04625153Updated Apr 13, 2026

RC18 in Patients With Relapsing Remitting Multiple Sclerosis:a Phase II Trial

A Phase 2 interventional study of RC18 160mg and RC18 240mg in Multiple Sclerosis, Relapsing-Remitting, sponsored by RemeGen Co., Ltd.. Terminated at 1 site in China. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by RemeGen Co., Ltd. · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor Strategic Priority Adjustment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
8
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

To observe the safety and effectivity of a Recombinant Human B Lymphocyte Stimulator Receptor : Immunoglobulin G( IgG ) Fc Fusion Protein for injection (RC18) in patients with relapsing remitting multiple sclerosis, analyze the dose-response relationship and provide a dose basis for follow-up clinical trials.

02

Conditions studied

  • Multiple Sclerosis, Relapsing-Remitting
03

In context

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

This study's enrollment of 8 is below the median of 66 across 437 interventional studies indexed under Multiple Sclerosis, Relapsing-Remitting.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Lead sponsor

RemeGen Co., Ltd. is the lead sponsor of 83 studies on the registry; 42 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with relapsing remitting multiple sclerosis meet the diagnostic criteria of McDonald 2017.
  • 18-55 years old, male or female
  • At least 1 recurrence was recorded within 1 year prior to randomization, or at least 2 recurrences within 2 years (the first clinical episode of MS was recorded as a recurrence), or active gadolinium enhanced lesions in the brain within 1 year prior to screening.
  • Neurological symptoms were stable for ≥30 days before screening and before baseline
  • EDSS score ≤ 5.5
  • signed voluntarily

Exclusion criteria

Exclusion Criteria:

  • Patients who were unable to undergo magnetic resonance imaging or who were allergic to gadolinium contrast agents during the trial
  • In addition to multiple sclerosis, patients with chronic active immune system diseases or who are stable but require immunotherapy ( and/or ) (e.g., rheumatoid arthritis, scleroderma, Sjogren's syndrome, Crohn's disease, ulcerative colitis), Or patients with known immunodeficiency syndromes (AIDS, genetic immunodeficiency, and drug-induced immunodeficiency); Patients who received glucocorticoid maintenance therapy before randomization could participate in the trial after discontinuing the drug.
  • Patients who were AQP4 antibody positive and/or MOG antibody positive within 1 year prior to randomization
  • Patients who have received the following treatment:

    1. Interferon, pegylated interferon, glatirex acetate, and dimethyl fumarate were used within 4 weeks prior to randomization.
    2. Use of Fingomod, intravenous immunoglobulin, or plasmapheresis within 12 weeks prior to randomization.
    3. Alemtuzumab, Daclizumab, Ocrelizumab were administered within 24 weeks prior to randomization.
    4. Azathioprine (AZA, half-life t1/2=6hrs), Mycophenolate Mofetil (t1/2=16hrs), Leflunomide (LEF, LEflunomide) were used before randomization. t1/2=15 days), Tacrolimus (t1/2=43 hrs), Teriflunomide (t1/2=18 days), Cyclosporin (CsA) Patients with immunosuppressants such as t1/2=27 hrs), Methotrexate (MTX, t1/2=14hrs), Cyclophosphamide (CTX, t1/2=6hrs), in addition to leflunomide and teriflunomide, The discontinuation interval was more than 5 times the half-life. Leflunomide and Teriflunomide need to be eluted with coletenide, which can be discontinued and the following measures taken: Coletenide 8 g 3 times daily for 11 days, if the 8 g dose is not tolerated, can be changed to 4 g orally for the same time and frequency as before.
    5. Use of clatribine or mitoxantrone within 1 year prior to randomization.
    6. Received lymphoid irradiation and bone marrow transplantation before randomization.
  • Patients were participated in any clinical trial 28 days before randomization or within 5 times half-life of study drug participating in clinical trial (whichever is longer).
  • Patients with any persistent or chronic active infection or serious infection history in the screening period, such as shingles; active tuberculosis (patients with latent tuberculosis can participate in the test if they are given isoniazid and / or rifampin at the same time); infection; syphilis antibody positive; antibody positive; positive; HBsAg negative but HBcAb positive, the HBV-DNA quantitative test is needed. If the HBV-DNA is positive, the patient should be excluded. If the HBV-DNA is negative, the patient can not be excluded.
  • The results of abnormal laboratory tests to be excluded include but are not limited to: Leukocyte count \< 3 × 10\~9 / L; neutrophil \< 1.5 × 10\~9 / L; \< 85g / L; count \< 80 × 10\~9 / L; serum creatinine > 1.5 × , accompanied by \< 50ml / min (measured value, or calculated by Cockcroft Gault formula); total > 1.5 × ULN; > 3 × ULN; AST > 3 × ULN; alkaline phosphatase > 2 × ULN; IgG \< lower limit of normal value; IgM \< lower limit of normal value;
  • Cancer patients
  • Pregnant women, lactating women and patients with family planning during the trial
  • Patients with other mental disorders
  • Patients who experienced any of the following events within 12 weeks before randomization: myocardial infarction, unstable ischemic heart disease, stroke, or class IV heart failure
  • The researchers believe that the patients are compliant insufficiently or not suitable to participate in this study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    RC18 160mg

    RC18 160mg is injected subcutaneously once a week for 48 times.

    Biological: RC18 160mg

  • Experimental
    RC18 240mg

    RC18 240mg is injected subcutaneously once a week for 48 times.

    Biological: RC18 240mg

Interventions

  • BiologicalRC18 160mg

    RC18 160mg is injected subcutaneously once a week for 48 times.

    Also known as: telitacicept

  • BiologicalRC18 240mg

    RC18 240mg is injected subcutaneously once a week for 48 times.

    Also known as: telitacicept

06

What researchers measure

Primary outcomes

  1. 48-week annual recurrence rate (ARR)

    48-week annual recurrence rate (ARR). ARR is calculated as the total number of relapses for all subjects divided by the total number of years of subjects receiving this treatment

    Time frame: 0- 48 weeks

Secondary outcomes

  1. 24 weeks confirmed disability progression

    Time to 24 weeks confirmed disability progression (24wCDP) (based on EDSS assessment)

    Time frame: 0-24weeks

  2. 12 weeks confirmed disability progression

    Time to 12 weeks confirmed disability progression (12wCDP) (based on EDSS assessment)

    Time frame: 0-12weeks

  3. 12 weeks confirmed disability improvement

    Time to 12 weeks confirmed disability improvement (12wCDI) (based on EDSS assessment)

    Time frame: 0-12weeks

  4. Changes in EDSS scores from baseline at weeks 12, 24, 36 and 48

    Changes in EDSS scores from baseline at weeks 12, 24, 36 and 48; Gadolinium enhanced T1 lesion number in the brain compared with baseline at weeks 12, 24, 36, and 48

    Time frame: At 12, 24, 36 and 48 weeks

  5. Number of new low-signaling T1 lesions in the brain

    Number of new low-signaling T1 lesions in the brain at weeks 12, 24, 36, and 48 compared with baseline

    Time frame: At 12, 24, 36 and 48 weeks

  6. Number of new/new large T2 lesions in the brain

    Number of new/new large T2 lesions in the brain at weeks 12, 24, 36, and 48 compared with baseline

    Time frame: At 12, 24, 36 and 48 weeks

  7. Proportion of patients without recurrence at weeks 0 to 48

    Proportion of patients without recurrence at weeks 0 to 48

    Time frame: 0- 48 weeks

07

Study locations

1 site
  • the Third Affiliated Hospital,Sun Yat-Sen University
    Guangzhou, Guangdong, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2021 to primary completion in Apr 2026, 58 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2020
First posted
Nov 12, 2020
StartActual
May 13, 2021
Primary completionActual
Apr 3, 2026
CompletionActual
Apr 3, 2026
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04625153
Lead sponsor
RemeGen Co., Ltd.
Responsible party
Sponsor
First posted
Nov 12, 2020
Start date
May 13, 2021
Primary completion
Apr 3, 2026
Completion
Apr 3, 2026
Last update
Apr 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Telitacicept

Start the discussion